Penserra Capital Management LLC Takes Position in Sanofi (NASDAQ:SNY)

Posted by on Feb 28th, 2023

Penserra Capital Management LLC purchased a new stake in shares of Sanofi (NASDAQ:SNY – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 960 shares of the company’s stock, valued at approximately $36,000.

Several other large investors have also made changes to their positions in the company. Fairfield Bush & CO. bought a new stake in Sanofi in the first quarter valued at about $26,000. Eagle Bay Advisors LLC acquired a new stake in Sanofi during the 2nd quarter worth about $28,000. Pinnacle Bancorp Inc. grew its holdings in Sanofi by 53.2% during the 3rd quarter. Pinnacle Bancorp Inc. now owns 855 shares of the company’s stock worth $33,000 after acquiring an additional 297 shares during the period. Ronald Blue Trust Inc. acquired a new stake in Sanofi during the 2nd quarter worth about $34,000. Finally, Curi Wealth Management LLC acquired a new stake in shares of Sanofi in the 2nd quarter valued at about $43,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Price Performance

Sanofi stock opened at $47.85 on Tuesday. Sanofi has a 52 week low of $36.91 and a 52 week high of $58.10. The company’s 50 day moving average price is $48.20 and its two-hundred day moving average price is $44.04. The company has a quick ratio of 0.55, a current ratio of 1.42 and a debt-to-equity ratio of 0.20. The stock has a market cap of $120.66 billion, a P/E ratio of 16.91, a P/E/G ratio of 1.47 and a beta of 0.56.

Sanofi (NASDAQ:SNY – Get Rating) last posted its quarterly earnings results on Friday, February 3rd. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The company had revenue of $10.95 billion during the quarter, compared to the consensus estimate of $11.51 billion. Sanofi had a return on equity of 28.31% and a net margin of 15.70%. On average, equities analysts predict that Sanofi will post 4.4 earnings per share for the current year.

Sanofi Cuts Dividend

The business also recently declared an annual dividend, which will be paid on Friday, June 23rd. Investors of record on Wednesday, May 31st will be issued a $1.377 dividend. The ex-dividend date of this dividend is Tuesday, May 30th. This represents a dividend yield of 2.94%. Sanofi’s dividend payout ratio (DPR) is presently 44.52%.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. The Goldman Sachs Group assumed coverage on Sanofi in a research note on Friday, December 16th. They issued a “buy” rating for the company. Morgan Stanley reiterated an “overweight” rating on shares of Sanofi in a research note on Tuesday, December 13th. Finally, TheStreet upgraded Sanofi from a “c+” rating to a “b-” rating in a research note on Friday, December 2nd. Five investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Sanofi presently has an average rating of “Moderate Buy” and an average target price of $102.88.

Sanofi Profile

(Get Rating)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.

Featured Stories

Institutional Ownership by Quarter for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.